10/13/2009

A clinical study found colorectal cancer patients with a mutant KRAS gene have reduced progression-free survival time with anti-EGFR inhibitor panitumumab therapy, adding to earlier similar results for cetuximab. Experts said the data reinforce the importance of determining the molecular biology of colorectal tumors.

Related Summaries